Anker Enters the OTC Hearing Aid Market with Its First Regulated Audio Device
Anker announced its first over-the-counter hearing aids at IFA 2026 on September 3, stepping into a category that has seen both regulatory momentum and commercial turbulence. The Verge's senior reviewer John Higgins reported the announcement, which marks Anker's first move beyond consumer audio into regulated medical-adjacent hardware.
The devices use a receiver-in-canal (RIC) design, where the main body sits behind the ear and a thin tube carries sound into the ear canal. RIC is a well-established form factor in prescription hearing aids, popular for its balance of power, comfort, and visual discretion. Anker's version includes four beam-forming microphones — microphones that use directional focusing to prioritize the voice of someone standing in front of the user — an approach already common in modern hearing aids and high-end earbuds.
Processing is handled by the Thus chip, which Anker first announced in April and shipped in its Soundcore Liberty 5 Pro earbuds. Repurposing a proprietary audio DSP (digital signal processor) from a consumer earbud into an OTC hearing aid is a notable engineering and supply-chain decision. The Thus chip presumably handles both the hearing-loss compensation algorithms and the beam-forming microphone processing, though Anker has not detailed the specific signal-processing pipeline.
Battery life is rated at up to 12 hours on a single charge, extending to 36 hours with the included charging case. Anker also claims a five-minute fast charge yields two additional hours of use, and asserts that this is the quickest fast-charge rate among competitors in the OTC hearing aid category. That claim has not been independently verified.
Anker did not disclose exact model names, US pricing, or availability timelines. More details are expected by the end of 2026.
The backdrop for this announcement is mixed. The FDA finalized its rule permitting over-the-counter sale of hearing aids in August 2022, opening a regulatory pathway that many expected would draw consumer-electronics companies into a category long dominated by specialized manufacturers. Nearly four years later, adoption has been uneven. Medicare still does not cover hearing aids as of 2026, leaving the full cost to consumers and reinforcing the appeal of lower-priced OTC alternatives.
More pointedly, LXE Hearing, the parent company of Eargo and Lexie Hearing, decided to end its US operations and exit the OTC hearing aid market roughly two months before Anker's IFA announcement. Two of the more visible OTC brands in the US collapsing under a single corporate umbrella is a stark reminder that regulatory green-lighting does not guarantee commercial viability. The OTC hearing aid market has proven harder to crack than the 2022 FDA rule suggested, with challenges spanning insurance reimbursement gaps, consumer awareness, fit-and-comfort issues, and competition from increasingly capable hearables — devices that blur the line between audio products and hearing assistance.
The broader context here is that Anker's entry should be examined against those difficulties. The company's core competency is consumer audio hardware at competitive prices, and the Thus chip's origins in the Liberty 5 Pro earbuds suggest Anker is leveraging existing silicon and acoustic engineering rather than building a hearing-aid-specific platform from scratch. That strategy could lower costs and speed time to market. Whether it produces devices that audiologists and users consider adequate for real-world hearing loss is a separate question, and one that will not be answered until the products reach consumers.
The decision to enter a market that LXE just exited is either contrarian or simply reflects a different cost structure and go-to-market approach. Anker's global distribution footprint, established brand recognition in consumer audio, and experience shipping tens of millions of earbuds give it advantages that smaller, hearing-aid-only companies lacked. But the OTC hearing aid category's difficulties have not been primarily about hardware capability. Reimbursement, clinical credibility, fitting workflows, and consumer trust are the friction points, and none of those are solved by a good chip or fast charging.
In this author's view, Anker's presence could bring meaningful price pressure to a category where devices often range from several hundred to a few thousand dollars. If Anker applies the aggressive pricing strategy that has characterized its Soundcore brand, OTC hearing aids could become meaningfully more accessible. The open question is whether Anker will invest in the software, support, and fitting tools that make OTC hearing aids usable for people who do not have an audiologist guiding them, or whether it will treat these as another product line in a broad consumer-electronics portfolio.
For now, the announcement is more signal of intent than product. Anker has the silicon, the form factor, and the distribution. What it does not yet have is a shipping product, a price, or a demonstrated approach to the parts of the hearing aid market that have tripped up predecessors.
